TMCV yields 2000000.00% · ABBV yields 3.06%● Live data
📍 TMCV pulled ahead of the other in Year 1
Combined, TMCV + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TMCV + ABBV for your $10,000?
Temecula Valley Bancorp Inc. operates as the bank holding company for Temecula Valley Bank that provides various banking products and services in California. Its deposit accounts include demand, savings, money market, and time accounts, as well as certificates of deposit. The company principally originates construction and/or real estate secured loans, including construction loans on one-to-four-family residences and commercial real estate properties; and land acquisition and development loans, as well as commercial and small business administration loans. Its lending portfolio also comprises consumer loans, such as automobile, recreational vehicle, boat, home improvement, home equity lines of credit, collateralized and uncollateralized personal, and deposit account collateralized loans. As of December 31, 2008, it operated 11 full-service offices in Temecula, Carlsbad, Corona, El Cajon, Escondido, Fallbrook, Murrieta, Ontario, Solana Beach, San Marcos, and the Rancho Bernardo area of San Diego. The company was founded in 1996 and is headquartered in Temecula, California. On November 6, 2009, Temecula Valley Bancorp Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the Central District of California.
Full TMCV Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.